Prothena | PRTA - Pre Tax Profit


Prothena reported $-21.58M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Exelixis USD 267.69M 15M Mar/2026
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
MacroGenics USD -14.93M 31.75M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Prothena USD -21.58M 15.33M Dec/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026
Xoma USD 15.98M 24.58M Jun/2024